Antibody against PcrV
US8501179B2 · kind B2 · utility
3Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2009 |
| Grant date | Aug 6, 2013 |
| Priority date | — |
| Expiry date | Oct 22, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.